Immorta Bio Innovates with New StemCellRevivify™ Platform for Aging Regeneration
In a groundbreaking development for longevity science, Immorta Bio Inc. has expanded its StemCellRevivify™ platform to harness the potential of autologous mitochondria from younger cells. This innovative approach targets the regeneration of vital organs such as the heart, brain, and liver, presenting a promising avenue for treating age-related diseases. The company, which is committed to redefining how we treat aging and its associated diseases, announced this advance on October 23, 2025.
Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized the company’s commitment to a transformative therapeutic strategy with the mantra "Out with the old, In with the new." This philosophy underscores their senolytic immunotherapy, SenoVax™, which effectively targets and eliminates senescent cells responsible for driving the aging process and related diseases. The novel aspect of this approach involves the utilization of personalized mesenchymal stem cells (pMSC) generated through their StemCellRevivify™ technology, ensuring that regenerated cells originate from the patient’s own biology.
The recent patent application filed by Immorta Bio illustrates the process of producing young pMSC from aged mice blood, from which mitochondria were isolated. This crucial step has led to significant therapeutic effects in preclinical models, particularly in cases of heart failure, brain injuries caused by radiation, and liver failure. These findings mark a significant breakthrough in regenerative medicine, hinting at a future where patients can rely on their own cells to restore health and vitality.
The clinical landscape for these advancements is equally promising. Immorta Bio is preparing to initiate clinical trials of SenoVax™ to combat lung cancer, where tumors exploit senescent cell mechanisms to evade immune responses, showcasing the potential dual benefits of combining SenoVax™ with StemCellRevivify™ technology. This synergistic treatment could pave the way for more effective therapies targeting not only cancer but also disorders of consciousness, such as coma, as discussed in the peer-reviewed publication titled "Reversing Coma by Senolytics and Stem Cells The Future is Now," featured in the Journal of Translational Medicine.
Chairman and CEO Dr. Boris N. Reznik highlighted Immorta Bio's revolutionary approach, stating, “We are shaking the foundations of medicine by treating aging as a disease we can effectively address. Our integrated technologies don't merely regenerate cells and organs; they redefine the very essence of human potential.”
With its headquarters in Miami Beach, Florida, Immorta Bio is strategically positioned to lead a burgeoning industry focused on longevity, transforming scientific innovations into real health solutions. As the company accelerates its clinical trials and seeks to solidify its foothold in this emerging multi-billion-dollar market, it stands at the forefront of a scientific revolution that seeks not just to extend life, but to improve the quality of life as we age.
In conclusion, as Immorta Bio continues to develop and refine its StemCellRevivify™ platform alongside SenoVax™, it exemplifies a new era in medical science—a future where aging may no longer dictate the trajectory of human health and vitality. The implications of these advancements are profound, and as they move closer to clinical application, the potential to rewrite the aging narrative becomes increasingly tangible.
Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized the company’s commitment to a transformative therapeutic strategy with the mantra "Out with the old, In with the new." This philosophy underscores their senolytic immunotherapy, SenoVax™, which effectively targets and eliminates senescent cells responsible for driving the aging process and related diseases. The novel aspect of this approach involves the utilization of personalized mesenchymal stem cells (pMSC) generated through their StemCellRevivify™ technology, ensuring that regenerated cells originate from the patient’s own biology.
The recent patent application filed by Immorta Bio illustrates the process of producing young pMSC from aged mice blood, from which mitochondria were isolated. This crucial step has led to significant therapeutic effects in preclinical models, particularly in cases of heart failure, brain injuries caused by radiation, and liver failure. These findings mark a significant breakthrough in regenerative medicine, hinting at a future where patients can rely on their own cells to restore health and vitality.
The clinical landscape for these advancements is equally promising. Immorta Bio is preparing to initiate clinical trials of SenoVax™ to combat lung cancer, where tumors exploit senescent cell mechanisms to evade immune responses, showcasing the potential dual benefits of combining SenoVax™ with StemCellRevivify™ technology. This synergistic treatment could pave the way for more effective therapies targeting not only cancer but also disorders of consciousness, such as coma, as discussed in the peer-reviewed publication titled "Reversing Coma by Senolytics and Stem Cells The Future is Now," featured in the Journal of Translational Medicine.
Chairman and CEO Dr. Boris N. Reznik highlighted Immorta Bio's revolutionary approach, stating, “We are shaking the foundations of medicine by treating aging as a disease we can effectively address. Our integrated technologies don't merely regenerate cells and organs; they redefine the very essence of human potential.”
With its headquarters in Miami Beach, Florida, Immorta Bio is strategically positioned to lead a burgeoning industry focused on longevity, transforming scientific innovations into real health solutions. As the company accelerates its clinical trials and seeks to solidify its foothold in this emerging multi-billion-dollar market, it stands at the forefront of a scientific revolution that seeks not just to extend life, but to improve the quality of life as we age.
In conclusion, as Immorta Bio continues to develop and refine its StemCellRevivify™ platform alongside SenoVax™, it exemplifies a new era in medical science—a future where aging may no longer dictate the trajectory of human health and vitality. The implications of these advancements are profound, and as they move closer to clinical application, the potential to rewrite the aging narrative becomes increasingly tangible.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.